Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

Cellosaurus NS0 (CVCL_3940)

[Text version]
Cell line name NS0
Synonyms NSO; NS/0; NS/O
Accession CVCL_3940
Resource Identification Initiative To cite this cell line use: NS0 (RRID:CVCL_3940)
Comments Group: Hybridoma fusion partner cell line.
Characteristics: Commonly employed for monoclonal antibody expression.
Characteristics: Lacks endogenous glutamine synthetase (GS) activity.
Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
Disease Mouse plasma cell myeloma (NCIt: C125417)
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: BALB/c.
Hierarchy Parent: CVCL_2155 (P3/NS1/1-Ag4.1)
CVCL_6494 (022HU-NSO)CVCL_C7IX (10/16)CVCL_C7IY (10/8)
CVCL_C4FE (10C11)CVCL_A0HG (10E4)CVCL_C4FF (10F7 [Mouse hybridoma against phOX])
CVCL_C4EU (10G10)CVCL_C7IZ (11/32)CVCL_C7J0 (11/34)
CVCL_C7J1 (11/64)CVCL_LC04 (11BD-2E11-2)CVCL_C4FG (11G11)
CVCL_C4EV (11G3)CVCL_C7HY (11H9 [Mouse hybridoma against human CA9])CVCL_C4EW (12C4)
CVCL_C4EX (12G10)CVCL_C7HZ (12H8)CVCL_C4EY (13D4 [Mouse hybridoma against phOX])
CVCL_C4FH (13G7)CVCL_C4EZ (14C7)CVCL_C4F0 (14F10)
CVCL_A0HH (16A3)CVCL_C4FI (16C3)CVCL_C4FJ (17B6)
CVCL_DN54 (17G1)CVCL_C4F1 (18G8)CVCL_C4FK (19E11)
CVCL_A0HV (1A-3187)CVCL_A0HW (1A-4246)CVCL_LC05 (1A245.6)
CVCL_A0HX (1B-3246)CVCL_A0HY (1B-3440)CVCL_A0HZ (1B-4863)
CVCL_A0IA (1B-4971)CVCL_A0HI (1B5 [Mouse hybridoma against human RPSA])CVCL_CZ91 (1CB4)
CVCL_A0HJ (1D2 [Mouse hybridoma against human RPSA])CVCL_B6TF (1D4 [Mouse hybridoma against influenza D virus HE])CVCL_C4SV (1D5)
CVCL_B6TP (1E1 [Mouse hybridoma against influenza D virus HE])CVCL_C4SW (1F3 [Mouse hybridoma against human PTHLH])CVCL_A0CA (1G10 [Mouse hybridoma against HIV-1 rev])
CVCL_A0CB (1G7 [Mouse hybridoma against HIV-1 rev])CVCL_C4FL (1G7 [Mouse hybridoma against phOX])CVCL_J659 (2-179-E11)
CVCL_9149 (20C2)CVCL_C4F2 (20G9)CVCL_A0HK (21H1)
CVCL_C4F3 (2B2)CVCL_C7I0 (2C7 [Mouse hybridoma against human CA9])CVCL_C4F4 (2C7 [Mouse hybridoma against phOX])
CVCL_C7I1 (2D7)CVCL_B6TG (2E11 [Mouse hybridoma against influenza D virus HE])CVCL_B6TH (2E12 [Mouse hybridoma against influenza D virus HE])
CVCL_B6TI (2E3)CVCL_B6TJ (2E9 [Mouse hybridoma against influenza D virus HE])CVCL_C4SX (2F1 [Mouse hybridoma against human PTHLH])
CVCL_C4SY (2H3)CVCL_A0HL (2H9 [Mouse hybridoma against human RPSA])CVCL_J666 (357-101-4)
CVCL_J667 (357-167-24)CVCL_J668 (359-238-8)CVCL_J669 (359-81-11)
CVCL_C4F5 (3B6 [Mouse hybridoma against phOX])CVCL_C4FM (3C5 [Mouse hybridoma against phOX])CVCL_C4F6 (3E3)
CVCL_A0HM (3E6 [Mouse hybridoma against human RPSA])CVCL_C4F7 (3F2 [Mouse hybridoma against phOX])CVCL_B6TK (3G3 [Mouse hybridoma against influenza D virus HE])
CVCL_A0HN (3G5 [Mouse hybridoma against human RPSA])CVCL_2H34 (3NB12.13)CVCL_G693 (41-2)
CVCL_C7I2 (4A2 [Mouse hybridoma against human CA9])CVCL_C4SZ (4B10)CVCL_A0HP (4C11 [Mouse hybridoma against human RPSA])
CVCL_C4T0 (4E9)CVCL_A0HQ (4F6 [Mouse hybridoma against human RPSA])CVCL_C4T1 (4F9 [Mouse hybridoma against human PTHLH])
CVCL_B6TL (4G4 [Mouse hybridoma against influenza D virus HE])CVCL_G694 (50-6)CVCL_J061 (53B3)
CVCL_J062 (54B3)CVCL_C4SQ (5A)CVCL_C4SR (5C)
CVCL_C4T2 (5C10)CVCL_C4F8 (5C3)CVCL_C4T3 (5D11 [Mouse hybridoma against human PTHLH])
CVCL_C4T4 (5D3 [Mouse hybridoma against human PTHLH])CVCL_B6TM (5D4)CVCL_B6TN (5D6 [Mouse hybridoma against influenza D virus HE])
CVCL_C4T5 (5F8 [Mouse hybridoma against human PTHLH])CVCL_C4FN (5F9)CVCL_C4F9 (5G11 [Mouse hybridoma against phOX])
CVCL_C4T6 (5H1)CVCL_XI16 (6/22-10-30-13)CVCL_C4FP (6B10)
CVCL_C4SS (6C)CVCL_B6ZE (6F3H)CVCL_C4FQ (6F7 [Mouse hybridoma against phOX])
CVCL_C4FA (6G11 [Mouse hybridoma against phOX])CVCL_A0HR (7A5)CVCL_C4FB (7B10)
CVCL_G696 (7E12H12)CVCL_A0HS (8E4 [Mouse hybridoma against human RPSA])CVCL_A0CC (8E7 [Mouse hybridoma against HIV-1 rev])
CVCL_C4FR (8G6 [Mouse hybridoma against phOX])CVCL_C7I3 (9B6)CVCL_C4ST (9D)
CVCL_A0HU (9D8 [Mouse hybridoma against human RPSA])CVCL_C4SU (9F [Mouse hybridoma against human PTHLH])CVCL_A0CD (9G2 [Mouse hybridoma against HIV-1 rev])
CVCL_C4FC (9G6 [Mouse hybridoma against phOX])CVCL_L815 (AFRC 17D1)CVCL_K191 (AFRC MAC 156)
CVCL_K192 (AFRC MAC 157)CVCL_K193 (AFRC MAC 158)CVCL_K194 (AFRC MAC 159)
CVCL_K195 (AFRC MAC 160)CVCL_K202 (AFRC MAC 257)CVCL_L827 (AFRC MAC 260)
CVCL_LB97 (AR40A603.13)CVCL_LH69 (AR47A6.4.2)CVCL_C4YJ (AR51A165.2)
CVCL_LH70 (AR52A301.5)CVCL_LB98 (AR53A10.11)CVCL_LB99 (AR58A258.8)
CVCL_LC00 (AR58A314.1)CVCL_1954 (BA-D5)CVCL_1955 (BA-F8)
CVCL_G695 (BA-G5)CVCL_1960 (BF-32)CVCL_1961 (BF-34)
CVCL_1962 (BF-45)CVCL_KA95 (BF-B6)CVCL_1963 (BF-F3)
CVCL_1964 (BF-G6)CVCL_G162 (BMAC-1)CVCL_G163 (BMAC-3)
CVCL_C7IJ (Clone-119)CVCL_C7IK (Clone-275)CVCL_C3BV (CS-56)
CVCL_VK51 (CT-1 [Mouse hybridoma against human TNF])CVCL_G692 (DII 33.1)CVCL_C4FS (E18)
CVCL_B6NX (EA2.31)CVCL_B6NY (EA5.12)CVCL_B6SD (FC-2.15)
CVCL_DF71 (HB 34-1)CVCL_A5YP (HET-37)CVCL_A9EN (HRP 16-1)
CVCL_A3CK (KT65)CVCL_L704 (LDS 73/LW1)CVCL_UW14 (Luc63.2.22)
CVCL_UW15 (Luc90)CVCL_D5DN (MAsg2)CVCL_J222 (MH01)
CVCL_K161 (NI 1 alpha 364/3B3-14)CVCL_K162 (NI 1 alpha 364/8C4-8)CVCL_J845 (NI 3 416/6C6-6)
CVCL_J846 (NI 3 416/7B5-5)CVCL_J847 (NI 4 426/1A6-10)CVCL_J848 (NI 4 426/7A3-3)
CVCL_J849 (NI 4 426/8B1-7)CVCL_J850 (NI G 386/3B6-12)CVCL_J851 (NI G 386/3D1-16)
CVCL_J852 (NI GM 465/7A6-37)CVCL_J853 (NORIg 7.16.2)CVCL_C4VR (NQ16.113.8)
CVCL_C4VS (NQ16.38.18)CVCL_C4VT (NQ17.10.24)CVCL_C4VU (NQ18.36.44)
CVCL_C4VV (NQ19.1.1)CVCL_C4VW (NQ19.16.37)CVCL_C4VX (NQ19.2.4)
CVCL_C4VY (NQ19.22.21)CVCL_C4VZ (NQ19.8.1)CVCL_C4WH (NQ22.10.17)
CVCL_C4WI (NQ22.15.18)CVCL_C4WJ (NQ22.16.4)CVCL_C4WK (NQ22.17.18)
CVCL_C4WL (NQ22.18.7)CVCL_C4WM (NQ22.33.4)CVCL_C4WN (NQ22.56.1)
CVCL_C4WP (NQ22.61.1)CVCL_C4WQ (NQ22.87.1)CVCL_C4WR (NQ22.9.11)
CVCL_C4WS (NQ22.9.24)CVCL_C4WT (NQ22.91.1)CVCL_C4WU (NQ5.3.3)
CVCL_C4WV (NQ5.4.3)CVCL_C4WX (NQ5.48.2)CVCL_C4WY (NQ5.57.3)
CVCL_C4WZ (NQ5.6.1)CVCL_C4X0 (NQ5.61.1)CVCL_C4X2 (NQ5.78.2)
CVCL_C4X4 (NQ5.82.2)CVCL_C4X5 (NQ5.89.4)CVCL_C4X6 (NQ5.91.1)
CVCL_C4X7 (NQ5.92.5)CVCL_C4X8 (NQ5.96.2)CVCL_C4X9 (NQ6.24.2)
CVCL_C4XB (NQ6.41.1)CVCL_C4XC (NQ6.8.3)CVCL_C4XE (NQ7.1.3)
CVCL_C4XF (NQ7.23.1)CVCL_C4XG (NQ7.24.6)CVCL_C4XH (NQ7.28.1)
CVCL_C4XI (NQ7.3.3)CVCL_C4XJ (NQ7.34.3)CVCL_C4XK (NQ7.40.1)
CVCL_C4XL (NQ7.41.3)CVCL_C4XM (NQ7.47.1)CVCL_C4XN (NQ7.5.3)
CVCL_C4XP (NQ7.51.3)CVCL_C4XQ (NQ7.56.2)CVCL_C4XR (NQ7.6.1)
CVCL_C4XT (NQ7.7.1)CVCL_C4XU (NQ8.5.3)CVCL_C4XV (NQ8.16.2)
CVCL_G346 (NS0-Turbodoma)CVCL_DD16 (NS0bcl-2)CVCL_U023 (OX-23)
CVCL_U024 (OX-24)CVCL_J181 (OX-26)CVCL_J183 (OX-29)
CVCL_J185 (OX-30)CVCL_J186 (OX-33)CVCL_J187 (OX-34)
CVCL_J188 (OX-35 clone 5)CVCL_J189 (OX-36 clone 3)CVCL_J191 (OX-39)
CVCL_J193 (OX-41)CVCL_J194 (OX-42)CVCL_J195 (OX-43)
CVCL_J196 (OX-44)CVCL_J197 (OX-45)CVCL_U025 (OX-46)
CVCL_J198 (OX-47)CVCL_X512 (OX-48)CVCL_J199 (OX-49)
CVCL_J200 (OX-50)CVCL_J201 (OX-52)CVCL_J202 (OX-53)
CVCL_J203 (OX-54)CVCL_J204 (OX-55)CVCL_J209 (OX-60)
CVCL_J210 (OX-61)CVCL_J211 (OX-62)CVCL_J212 (OX-68)
CVCL_D3N8 (PSMA 10.3)CVCL_2183 (RV-C2)CVCL_2184 (SC-71)
CVCL_2185 (SC-75)CVCL_2216 (TI-1 [Mouse hybridoma])CVCL_B7NK (TI-3)
CVCL_2217 (TI-4)CVCL_KA81 (VPM 1)CVCL_KA82 (VPM 14)
CVCL_KA83 (VPM 15)CVCL_KA84 (VPM 16)CVCL_KA85 (VPM 17)
CVCL_G164 (VPM 18)CVCL_G165 (VPM 19)CVCL_KA89 (VPM 29)
CVCL_KA86 (VPM 3)CVCL_KR64 (VPM 30)CVCL_G166 (VPM 36)
CVCL_G167 (VPM 37)CVCL_G168 (VPM 38)CVCL_KA87 (VPM 39)
CVCL_KA88 (VPM 4)CVCL_G169 (VPM 40)CVCL_G170 (VPM 41)
CVCL_G171 (VPM 43)CVCL_G172 (VPM 44)CVCL_G173 (VPM 45)
CVCL_G174 (VPM 46)CVCL_G175 (VPM 47)CVCL_G176 (VPM 48)
CVCL_G177 (VPM 5)CVCL_G178 (VPM 54)CVCL_G179 (VPM 6)
CVCL_G180 (VPM 8)
Sex of cell Female
Category Cancer cell line
Web pages https://en.wikipedia.org/wiki/NS0_cell

PubMed=19003032; DOI=10.1007/s10616-005-3563-z
Zhang J.-Y., Robinson D.
Development of animal-free, protein-free and chemically-defined media for NS0 cell culture.
Cytotechnology 48:59-74(2005)

PubMed=18617141; DOI=10.1016/j.jprot.2008.02.003
de la Luz-Hernandez K.R., Rojas-del Calvo L., Rabasa-Legon Y., Lage-Castellanos A., Castillo-Vitlloch A., Diaz J., Gaskell S.J.
Metabolic and proteomic study of NS0 myeloma cell line following the adaptation to protein-free medium.
J. Proteomics 71:133-147(2008)

Cell line collections (Providers) ECACC; 85110503
NCBI_Iran; C142
RCB; RCB0213
TKG; TKG 0594
Cell line databases/resources CLO; CLO_0008203
CLO; CLO_0008206
CLO; CLO_0050179
CLDB; cl3737
CLDB; cl3738
CLDB; cl3739
FCS-free; 110-17-508-1-16-3
Lonza; 757
Anatomy/cell type resources BTO; BTO:0004968
Chemistry resources ChEMBL-Cells; CHEMBL3307752
ChEMBL-Targets; CHEMBL615003
PubChem_Cell_line; CVCL_3940
Encyclopedic resources Wikidata; Q20164415
Entry history
Entry creation04-Apr-2012
Last entry update21-Mar-2023
Version number16